On October 19, 2023, the Commission imposed fines totalling €13.4 million on five pharmaceutical companies (Alkaloids of Australia, Alkaloids Corporation, Boehringer, Linnea, and Transo-Pharm) for their participation in a cartel in relation to an active pharmaceutical ingredient.[1]  This is the Commission’s first-ever cartel decision in the pharmaceutical sector, adding to the Commission’s extensive enforcement action against pharmaceutical companies.